<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942734</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0567</org_study_id>
    <secondary_id>NCI-2012-01643</secondary_id>
    <nct_id>NCT00942734</nct_id>
  </id_info>
  <brief_title>Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if RAD001 in combination with Tarceva
      (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The
      safety of this drug combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new
      blood vessels that help tumor growth, and this may cause the tumor cells to die.

      Erlotinib hydrochloride is designed to block the activity of a protein found on the surface
      of many tumor cells that may control tumor growth and survival. This may stop tumors from
      growing.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will take 1 RAD001 tablet and
      1 erlotinib hydrochloride tablet every day of each 28 day study &quot;cycle&quot;.

      Both drugs should be taken at the same time, by mouth, with a cup (8 ounces) of water. You
      should take the drugs at least 1 hour before or 2 hours after eating. You should take the
      study drugs at around the same time each day. Your eating habits around the time you take the
      drugs should stay the same while you are on study. lf you vomit, you should not take another
      tablet until your next scheduled dose.

      Tell your doctor if you have any side effects, as your dose(s) of study drug(s) may be
      lowered or stopped for a few days. You may be given drugs to help reduce the risk of side
      effects.

      Study Visits:

      On Day 1 (+/- 3 days) of each cycle, the following tests and procedures will be performed:

        -  You will have a complete physical exam, including measurement of your weight and vital
           signs.

        -  You will be asked about any drugs you may be taking and any side effects you may be
           having.

        -  Your performance status will be recorded.

        -  Blood (about 3 teaspoons) will be drawn for routine tests. If your doctor thinks it is
           needed, you may have to have these blood tests more often.

      On Day 1 (+/- 3 days) of every evenly numbered cycle (Cycles 2, 4, 6, and so on), you will
      have a CT scan or MRI scan to check the status of the disease.

      Length of Study:

      You may continue to take the study drugs for as long as you are benefitting. You will be
      taken off study if the disease gets worse or if you have intolerable side effects.

      End-of-Study Visit:

      When you go off study for any reason, you will have an end-of-study visit. The following
      tests and procedures will be performed:

        -  Your medical history will be recorded.

        -  You will have a complete physical exam, including measurement of your weight and vital
           signs.

        -  You will be asked about any drugs you may be taking and any side effects you may be
           having.

        -  Your performance status will be recorded.

        -  Blood (about 3 teaspoons) will be drawn for routine tests.

        -  You will have a CT scan or MRI scan to check the status of the disease.

      Follow-Up:

      You will be called within 30 days after the end-of-study visit and asked how you are doing
      and about any possible side effects that you may have had. The call should take about 5
      minutes.

      This is an investigational study. RAD001 is FDA approved and commercially available for the
      treatment of certain types of breast cancer. Erlotinib hydrochloride is FDA approved and
      commercially available for the treatment of advanced non-small cell lung carcinoma (NSCLC)
      and advanced pancreatic cancer. The use of this drug combination for the treatment of HNSCC
      is investigational.

      Up to 35 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-Week Progression-Free Survival (PFS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tumor assessments performed by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) after 4 weeks, 12 weeks, then every 8 weeks thereafter. Participants who received at least one dose of RAD001+erlotinib and who die before 12 weeks, counted as having progressive disease. Response Evaluation Criteria in Solid Tumors (RECIST) defined as Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. Progression-free survival defined as stable disease or better. Progressive Disease (PD): &gt;20% increase in sum of LD of target lesions, taking as reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Head And Neck Cancer</condition>
  <arm_group>
    <arm_group_label>RAD001 + Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>One tablet (150 mg) by mouth every day of each 28 day study cycle.</description>
    <arm_group_label>RAD001 + Erlotinib</arm_group_label>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>1 tablet (5 mg) by mouth every day of each 28 day study cycle.</description>
    <arm_group_label>RAD001 + Erlotinib</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed squamous cell carcinoma of the head and neck

          2. Patients that have failed one platinum-containing chemotherapy regimen with or without
             EGFR inhibitor and/or epidermal growth factor receptor (EGFR) inhibitor as systemic
             therapy for recurrent/metastatic disease. Prior investigational therapy (with the
             exclusion of mammilian target of rapamycin (mTOR) inhibitor) allowed but at least 4
             weeks must have elapsed with recovery from all toxicities

          3. Patients who had prior induction or concurrent chemotherapy delivered as part of their
             primary treatment are eligible as long as they have completed primary therapy at least
             6 months prior to study entry.

          4. Patients must have at least one measurable site of disease according to Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously
             irradiated. If the patient has had previous radiation to the marker lesion(s), there
             must be evidence of progression since the radiation

          5. Age &gt;/= 18 years

          6. Minimum of two weeks since any major surgery or completion of radiation. Note:
             Patients may have received prior radiation therapy to tumor sites that will not be
             assessed for response, unless there is evidence of progression.

          7. Completion of all prior systemic anticancer therapy for the treatment of
             recurrent/metastatic disease (adequately recovered from the acute toxicities of any
             prior therapy) at least 4 weeks prior to study entry

          8. Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2

          9. Laboratory Values (within 14 days prior to administration of study drugs): Adequate
             bone marrow function as shown by: absolute neutrophil count (ANC) &gt;/= 1.5 * 10^9/L,
             Platelets &gt;/= 100 * 10^9/L, Hgb &gt; 10 g/dL; Adequate liver function as shown by: serum
             bilirubin &lt;/=1.5 * upper limit of normal (ULN), and serum transaminases activity &lt;/= 3
             * ULN. With the exception of serum transaminases (&lt; 5 * ULN) if the patient has liver
             metastases

         10. Continued from Inclusion # 9: Fasting serum cholesterol &lt;/= 300 mg/dL OR &lt;/= 7.75
             mmol/L AND fasting triglycerides &lt;/= 2.5 * ULN. NOTE: In case one or both of these
             thresholds are exceeded, the patient can only be included after initiation of
             appropriate lipid lowering medication

         11. Signed informed consent

        Exclusion Criteria:

          1. Prior treatment with any investigational drug within the preceding 4 weeks,
             concomitant chemotherapy, hormonal therapy, radiotherapy or immunotherapy, or therapy
             with agents otherwise used in treatment of cancer (for example, methotrexate for
             rheumatoid arthritis)

          2. Chronic treatment with systemic steroids or another immunosuppressive agent. Steroids
             will not be allowed and should be discontinued 24 hours prior to initiation of
             treatment on protocol. An exception for replacement steroids prescribed for adrenal
             insufficiency will be allowed.

          3. Patients should not receive immunization with attenuated live vaccines during study
             period or within one week of study entry

          4. Patients with metastatic disease to the brain, unless treated and controlled and the
             patient is off steroids and/or antiepileptics for at least 3 weeks.

          5. Other malignancies within the past 2 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinomas of the skin.

          6. Patients with active skin, mucosa, ocular or gastrointestinal disorders grade &gt; 1

          7. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as: unstable angina
             pectoris, symptomatic congestive heart failure, myocardial infarction, &lt;/= 6 months
             prior to first study treatment, serious uncontrolled cardiac arrhythmia

          8. Continued from Exclusion #7: severely impaired lung function; uncontrolled diabetes as
             defined by fasting serum glucose &gt;1.5x ULN; any active (acute or chronic) or
             uncontrolled infection/ disorders.; nonmalignant medical illnesses that are
             uncontrolled or whose control may be jeopardized by the treatment with the study
             therapy; liver disease such as cirrhosis, chronic active hepatitis or chronic
             persistent hepatitis

          9. A known history of HIV or AIDS-related illness or previous seropositivity for the
             virus

         10. Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of study agents (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection).

         11. Patients with any condition which impairs the ability to swallow study agent intact

         12. Patients with an active, bleeding diathesis or on oral anti-vitamin K medication
             (except low dose coumarin)

         13. Women who are pregnant or breast feeding, or women/men able to conceive and unwilling
             to practice an effective method of birth control. (Women of childbearing potential
             (WOCP) must have a negative urine or serum pregnancy test within 7 days prior to
             administration of study drugs). WOCP: A female of child bearing potential is a
             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral
             oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive
             months (i.e., has had menses at any time in the preceding 24 consecutive months).

         14. (Continued from Exclusion # 13) Females must either commit to abstinence from
             heterosexual intercourse or use a barrier method of contraception. Oral, implantable,
             and injectable contraceptives may be affected by cytochrome P450 interactions, and are
             therefore not considered effective for this study. Males must either commit to
             abstinence from heterosexual intercourse or use a barrier method of contraception.

         15. Lack of resolution of all toxic manifestations of prior chemotherapy biologic therapy
             or radiation therapy.

         16. Patients who have received prior treatment with an mTor inhibitor.

         17. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins
             (sirolimus, temsirolimus) or to its excipients

         18. Patients with psychiatric illness or confusional status that may impair the patient's
             understanding of the informed consent

         19. Patients unwilling to or unable to comply with the protocol

         20. Patients with any condition which impairs the ability to swallow study agent intact
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vali Papadimitrakopoulou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2016</results_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>RAD001</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>OSI-774</keyword>
  <keyword>Tarceva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 17, 2009 to February 08, 2013. Recruitment was done in various medical clinics in the United States.</recruitment_details>
      <pre_assignment_details>Of the forty-nine participants registered, six participants were ineligible and not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RAD001 + Erlotinib</title>
          <description>RAD001 5 mg orally and Erlotinib 150 mg orally every day of each 28 day study cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RAD001 + Erlotinib</title>
          <description>RAD001 5 mg orally and Erlotinib 150 mg orally every day of each 28 day study cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12-Week Progression-Free Survival (PFS)</title>
        <description>Tumor assessments performed by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) after 4 weeks, 12 weeks, then every 8 weeks thereafter. Participants who received at least one dose of RAD001+erlotinib and who die before 12 weeks, counted as having progressive disease. Response Evaluation Criteria in Solid Tumors (RECIST) defined as Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. Progression-free survival defined as stable disease or better. Progressive Disease (PD): &gt;20% increase in sum of LD of target lesions, taking as reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started.</description>
        <time_frame>12 weeks</time_frame>
        <population>Eight participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001 + Erlotinib</title>
            <description>RAD001 5 mg orally and Erlotinib 150 mg orally every day of each 28 day study cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>12-Week Progression-Free Survival (PFS)</title>
          <description>Tumor assessments performed by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) after 4 weeks, 12 weeks, then every 8 weeks thereafter. Participants who received at least one dose of RAD001+erlotinib and who die before 12 weeks, counted as having progressive disease. Response Evaluation Criteria in Solid Tumors (RECIST) defined as Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. Progression-free survival defined as stable disease or better. Progressive Disease (PD): &gt;20% increase in sum of LD of target lesions, taking as reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started.</description>
          <population>Eight participants were not evaluable.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected through 12 weeks of treatment (Â± 3 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAD001 + Erlotinib</title>
          <description>RAD001 5 mg orally and Erlotinib 150 mg orally every day of each 28 day study cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PLATELETS LEVEL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PAIN (ORAL CAVITY)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>EDEMA: HEAD AND NECK</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FEVER WITHOUT NEUTROPINIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLESTEROL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vali Papadimitrakopoulou, MD</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

